- Roche’s BTK inhibitor may have reached ‘holy grail’ of brain penetration in phase 2 MS trial FierceBiotech
- Mesenchymal Stem Cell Therapy Shows Cognitive and Biomarker Improvements in Multiple Sclerosis Neurology Live
- Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Yahoo Finance
- Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data FierceBiotech
- Merck presents new Evobrutinib data at ECTRIMS | Merck Merck KGaA
- View Full Coverage on Google News
Read original article here